Company Overview
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +93.85% |
| 6 Months: | +3.15% |
| 3 Months: | +29.14% |
| 1 Month: | +3.85% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PCVX Vaxcyte, Inc. R2KR3KPHARMA | 61.16 | -8.02 | $9.10B | 0.00% | -33.02% | -36.51% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -13.94M | -12.23M | -12.14M | -15.84M | -27.60M | -21.22M | -21.31M | -19.45M | -23.14M | -23.73M | -26.95M | -39.22M | -47.89M | -58.58M | -71.19M | -87.15M | -113.03M | -114.47M | -152.98M | -139.92M | -180.79M | -226.22M | -242.38M | -345.85M | -302.78M |
| Net Income | -13.67M | -10.66M | -11.32M | -14.62M | -27.14M | -20.32M | -21.02M | -20.74M | -21.22M | -23.68M | -26.61M | -38.99M | -48.53M | -57.92M | -60.46M | -68.34M | -92.66M | -95.02M | -128.70M | -103.12M | -140.72M | -166.57M | -212.83M | -320.62M | -284.30M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.46 | -0.51 | -0.68 | -0.80 | -0.93 | -0.70 | -0.70 | -0.91 | -0.85 | -1.10 | -0.83 | -1.04 | -1.22 | -1.56 | -2.30 | -1.97 |
| R&D Expense | 12.63M | 9.97M | 9.63M | 13.38M | 24.32M | 18.18M | 16.41M | 14.66M | 17.26M | 17.65M | 20.43M | 31.68M | 38.47M | 47.68M | 58.08M | 72.69M | 97.42M | 94.59M | 131.51M | 116.94M | 148.13M | 194.18M | 209.93M | 312.78M | 267.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -35.53M | -54.15M | -89.58M | -103.67M | -232.26M | -468.04M | -569.55M | -923.67M |
| Net Income | -29.48M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M | -766.63M |
| Diluted EPS | - | - | -3.02 | -1.93 | -3.44 | -4.14 | -3.80 | -5.63 |
| R&D Expense | 30.14M | 45.61M | 73.56M | 78.41M | 169.45M | 332.34M | 476.64M | 794.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 65.70M | 392.83M | 324.34M | 1.01B | 1.41B | 3.51B | 3.00B |
| Total Equity | -29.13M | -57.73M | -106.37M | 345.84M | 284.02M | 953.61M | 1.24B | 3.31B | 2.69B |
| Cash & Equivalents | - | - | 58.98M | 386.20M | 68.98M | 834.66M | 397.45M | 387.88M | 173.96M |
| Total Liabilities | - | - | 11.76M | 46.98M | 40.32M | 52.56M | 167.45M | 205.50M | 317.21M |
| Current Liabilities | - | - | 11.05M | 46.86M | 28.72M | 40.52M | 145.34M | 140.18M | 205.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.47M | -47.15M | -46.63M | -121.39M | -170.60M | -296.79M | -452.63M | -655.58M |
| Investing Cash Flow | -1.77M | -1.20M | -1.10M | -212.31M | 74.58M | -773.31M | -2.01B | 437.35M |
| Financing Cash Flow | 62.19M | 41.57M | 374.87M | 17.80M | 861.55M | 639.81M | 2.45B | 2.01M |
| Capital Expenditure | -1.77M | -1.20M | -1.16M | -6.55M | -5.84M | -16.06M | -22.43M | -13.71M |
| Free Cash Flow | -32.24M | -48.34M | -47.78M | -127.95M | -176.44M | -312.85M | -475.05M | -669.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 51.1% | 47.3% | -25.8% | -35.2% | -23.4% | -32.4% | -14.0% | -28.5% |
| ROCE % | - | -99.1% | -25.9% | -35.1% | -24.1% | -37.1% | -16.9% | -33.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.01% | 20.85M | $1.25B |
| 2 | Jupiter Topco LLC | 12.07% | 17.97M | $1.07B |
| 3 | T. Rowe Price Investment Management, Inc. | 8.20% | 12.21M | $730.43M |
| 4 | Blackrock Inc. | 8.11% | 12.07M | $722.10M |
| 5 | RA Capital Management, L.P. | 7.71% | 11.47M | $686.58M |
| 6 | Wellington Management Group, LLP | 4.71% | 7.00M | $418.94M |
| 7 | Vanguard Portfolio Management LLC | 4.43% | 6.59M | $394.53M |
| 8 | Vanguard Capital Management LLC | 4.27% | 6.35M | $379.87M |
| 9 | State Street Corporation | 3.60% | 5.35M | $320.22M |
| 10 | Deep Track Capital, Lp | 2.89% | 4.30M | $257.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PCVX
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPNHQ0Vy1vbzZNVFZLZ2pydlllQlB6NjZvdXV2LTJ6LVpiaW1YVGNrU3hnNkQ1dVhIdUY1QkZUSzJlZVpsSmYzOGY5MzNBd3k5NVhseEx6SVlxVVd0SVZRTnc5UFpfSGhsNk5RZ3prZHlsQ1VhN3lmRmx5R1EtVjhLVHJZYkZISS1ZTU42Sn…
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQVjdDM3o1cGxacURBVzlTR0hMSnhnQ1BjSklCOVBGc19TWXNncGhqU0U2UkwyR19kTGRzR3hXYXQxNVVxbTk0eGlrajdtWEE5MlZISkdwa3lvZmY4c2pUcGZFNmt4dlM5aUkxMjlmdXp4UVI0SUtTR0dIdTViTTFZOTJPNHhBZ3QxeWxOcj…
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeVdHem80aVRSSE9Bb2dQMVg5YmUwRzVFT0tveVdaeTNtaHhTWGZta2FyNTJXaGNsbW5MYjNkVjRJQllwU0VWNnFPUGQ1QXloR2NCWFgyQmNGWENSS2hyQ2ZfellORFJXQU1INzlyYW9nNC1kUzVGUTJpT2JDSi1DRmJER2czX2FvQjZpQl…
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPZUdjMU03S01FRkpJRWxReGhaNG1HR0thTWl5cnIxWXVLMnQ2bGExUHd5bWNDRm4yanFxOVRESE50OGtMRUFURGNQMXBKTE9RYS0wTlZaZC1NeUhHb2lFRkFVd05XaFNlTTNZSmFCU2d5Z3F6bG1uSDQ1WVlROVAxQjhCZWRRQnc0VlRFN2…
Vaxcyte stock jumps on new executives, VAX-31 data timeline - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcnBnY2dwVzhZeVpTeFNXVi1KemNISXJrRldNTU5kQVI4MFNuUVo3OENxUEpvVmtTWHN6djJHQVFHNXc4ejctZ2VJVFZiWXVDamUwZEM4X3ZGVThTbXpKSDl3YnNjVkRFdXR1WDRfVElpLUZMMm5NaDdtY0QzUjNpMnhIS0ZXU3ktS1VfRG…
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNTENKV2tuaGVac2RCdi1jdDhabjd3cTUwajVySU5DalNYWnFJRzlEelZBaUF4aWk4cW5JWkJaTThkX2ZlcHBDVkp4Z0plaDVsWk50ZGxOV1d6Qm9SRkItbzlocEpOV1JRbmVYcUlRQkdPRDdiamUtcmNGWDNTLVhudlYzcG9uR184ZXA3V1…
PCVX — Frequently Asked Questions
What is the current share price of Vaxcyte, Inc. (PCVX)?
As of 2026-09-07 16:24 PDT, Vaxcyte, Inc. (PCVX) trades at $61.16 on NasdaqGS. Its 52-week range is $30.25 to $63.30.
What is the market capitalisation of PCVX?
Vaxcyte, Inc. (PCVX) has a market capitalisation of $9.10B on NasdaqGS.
What is the P/E ratio of PCVX?
PCVX trades at a trailing price-to-earnings (P/E) ratio of -8.02. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.80.
What is the return on equity (ROE) of PCVX?
PCVX has a return on equity (ROE) of -36.51%. Its return on capital employed (ROCE) is -33.02%.
Is PCVX a good stock to buy?
This page provides a data-driven analysis of Vaxcyte, Inc. (PCVX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.